BioCentury
ARTICLE | Preclinical News

RXR a potential minimal residual disease target in melanoma

July 13, 2018 11:28 PM UTC

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma.

Cancer relapse is driven by MRD, which is characterized by a small population of cancer cells with intrinsic resistance to treatment. Recent studies have suggested that the cells’ resistance is not caused by mutation, but by growth of cancer stem cell populations that are inherently drug-tolerant...